| Objective To analyze the clinical effect of zoledronic acid in the treatment of high turnover osteoporosis in the elderly patients and its effect on the markers of bone metabolism. Methods From January 2013 to January 2018, 66 elderly patients with osteoporosis in Liaoning Jinqiu Hospital were analyzed retrospectively, including 60 women and 6 men, aged 65-88 years, with an average age of (69.5 ± 9.8) years. All the elderly patients were high turnover type osteoporosis. They were divided into treatment group and control group. 32 patients were treated with zoledronic acid 5mg intravenously and calcitriol and calcium agent at the same time in the treatment group; 34 patients in the control group were only treated with calcitriol and calcium agent. In the treatment group, BMD, VAS, bone metabolism markers PINP and β - CTX were compared before and after treatment. The changes of BMD, VAS, PINP and β - CTX were compared between two groups. Observe the adverse drug reactions after treatment.Results There was no significant difference in age, gender, BMD and VAS between two groups before treatment (P > 0.05). In the treatment group, the BMD increased significantly after treatment (P < 0.05), and the VAS decreased significantly after treatment (P < 0.05). The levels of PINP and β - CTX decreased significantly (P < 0.05). Compared with the control group, BMD in the treatment group increased significantly at all time points after treatment (P < 0.05), VAS decreased significantly (P < 0.05), PINP and β - CTX decreased significantly (P < 0.05). During the treatment, 5 cases of fever and 2 cases of influenza-like symptoms appeared in the treatment group, all of which disappeared within 2-3 days. Conclusion Zoledronic acid can be used for the treatment of elderly patients to significantly improve the bone mineral density, effectively relieve pain, improve the level of bone metabolism markers, with less adverse drug reactions. |